Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight

The migraine market is forecast to grow at a 6% rate through 2036, according to DelveInsight. The article attributes the outlook to rising global migraine prevalence, improving diagnosis and awareness, and development of novel mechanisms beyond CGRP, including PACAP-targeted therapies, TRPA1 antagonists, and next-generation neuromuscular approaches.

Analysis

The investable signal is not the market-growth forecast itself, but whether mechanisms beyond CGRP expand the treatable pool or merely redistribute share among migraine therapies. PACAP, TRPA1 and neuromuscular approaches could benefit patients inadequately served by current options; if efficacy and tolerability are competitive, that may grow treatment use rather than simply displace CGRP products. Conversely, broader choice raises trial, launch and commercial-spend risk, while payers may require clear incremental benefit before reimbursing another branded therapy. Established CGRP players such as Eli Lilly and AbbVie could face future share pressure, but could also participate in market expansion; the article provides no pipeline or revenue evidence to distinguish those outcomes.

Treat the 2036 outlook as a promotional third-party forecast, not an earnings catalyst: no underlying methodology, pricing assumptions or clinical readouts are supplied. Over days, likely little durable stock impact. Over 1–3 months, monitor trial results and guidance for evidence of differentiated efficacy, safety and payer access. Over 6–18 months, successful non-CGRP therapies could broaden the category, but clinical failure, weak uptake or tighter reimbursement would reverse that thesis. The contrarian point: category growth does not guarantee shareholder returns if competition, rebates or R&D costs absorb the value. No company-level trade is justified on this item alone.

Key Decisions for Investors

• No directional trade from the forecast alone; do not treat a market-size estimate as evidence of near-term revenue or earnings revisions.
• Place PACAP-, TRPA1- and next-generation neuromuscular programs on a catalyst watchlist. Reassess only when trial data establish clinically meaningful differentiation and tolerability versus existing options.
• For Eli Lilly and AbbVie, monitor migraine-specific uptake, pricing/access commentary and pipeline updates rather than assuming either is a net winner or loser from category growth.
• Falsify the expansion thesis if late-stage data fail to show meaningful benefit, payer access is restrictive, or company commentary indicates weak adoption; strengthen it if differentiated results are followed by credible launch and reimbursement evidence.